Skip to content

Immunoclin Corp: 10-Q filed 2013-01-22

What Immunoclin Corp reported in its quarterly report filed 2013-01-22 (fiscal Q3 2012): 15 published measures, 52 facts as tagged in accession 0001078782-13-000154.

This filing

Form
10-Q (quarterly report)
Filed
2013-01-22
Fiscal period
fiscal Q3 2012
Accession
0001078782-13-000154 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Immunoclin Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-11-3023USD
At 2012-02-2912,386USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-11-3060,197USD
At 2012-02-2990,363USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-11-30-60,174USD
At 2012-02-29-77,977USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-11-3023USD
At 2012-02-2912,386USD
At 2011-11-3033USD
At 2011-02-289,000USD
At 2011-02-070USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-09-01 to 2012-11-30-5,705USD91
2012-03-01 to 2012-11-305,252USD275
2011-02-08 to 2012-11-30-85,445USD662
2011-09-01 to 2011-11-30-3,797USD91
2011-03-01 to 2011-11-30-42,884USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-03-01 to 2012-11-30-7,668USD275
2011-02-08 to 2012-11-30-38,076USD662
2011-03-01 to 2011-11-30-29,021USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-09-01 to 2012-11-300USD91
2012-03-01 to 2012-11-300USD275
2011-02-08 to 2012-11-300USD662
2011-09-01 to 2011-11-300USD91
2011-03-01 to 2011-11-300USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-03-01 to 2012-11-30-4,695USD275
2011-02-08 to 2012-11-3038,099USD662
2011-03-01 to 2011-11-3020,054USD275

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-09-01 to 2012-11-30-5,705USD91
2012-03-01 to 2012-11-30-34,248USD275
2011-02-08 to 2012-11-30-124,945USD662
2011-09-01 to 2011-11-30-3,797USD91
2011-03-01 to 2011-11-30-42,884USD275

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-09-01 to 2012-11-305,705USD91
2012-03-01 to 2012-11-3034,248USD275
2011-02-08 to 2012-11-30124,945USD662
2011-09-01 to 2011-11-303,797USD91
2011-03-01 to 2011-11-3042,884USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-11-305,361,015shares
At 2012-02-295,182,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-11-3019,910USD
At 2012-02-297,538USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-03-01 to 2012-11-305,252USD275
2011-02-08 to 2012-11-30-85,445USD662
2011-03-01 to 2011-11-30-42,884USD275

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-09-01 to 2012-11-30413USD91
2012-03-01 to 2012-11-302,372USD275
2011-02-08 to 2012-11-308,796USD662
2011-09-01 to 2011-11-302,388USD91
2011-03-01 to 2011-11-304,891USD275

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-03-01 to 2012-11-3012,551USD275
2011-02-08 to 2012-11-3025,271USD662
2011-03-01 to 2011-11-300USD275

Inspect the source

Entity
Immunoclin Corp / CIK 0001520047
Captured
SEC response SHA-256
cdfbf3ddd493bed046dd28be8c53e20201b60478d7022019645c6ed835ac7b05

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001520047.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))